NEW YORK (GenomeWeb News) – Immucor announced after the close of the market Tuesday that a US Food and Drug Administration committee has recommended that its platform for human erythrocyte antigen typing be cleared for clinical use.

The FDA's Blood Products Advisory Committee decided that Immucor's HEA Molecular BeadChip is "safe and effective" for typing HEA phenotypes in 35 blood group systems, the Norcross, Ga.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.